This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read KalVista Pharmaceuticals’s 8K filing here.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
See Also
- Five stocks we like better than KalVista Pharmaceuticals
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Intel: Is Now the Time to Be Brave?Â
- What Are the U.K. Market Holidays? How to Invest and Trade
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Roth IRA Calculator: Calculate Your Potential Returns
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
